助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   tacrolimus 在 泌尿科学 分类中 的翻译结果: 查询用时:0.009秒
图标索引 在分类学科中查询
所有学科
泌尿科学
药学
皮肤病与性病
外科学
肿瘤学
内分泌腺及全身性疾病
感染性疾病及传染病
消化系统疾病
有机化工
更多类别查询

图标索引 历史查询
 

tacrolimus
相关语句
  他克莫司
    Objective To investigate the feasibility and safety of substituting tacrolimus(FK506) for cyclosporin A(CsA) on delaying the pace of renal dysfunction in patients with biopsy-proven chronic allograft nephropathy(CAN).
    目的:探讨他克莫司(FK506)替换环孢素A(CsA)治疗慢性移植肾肾病(CAN)的有效性及安全性。
短句来源
    Objective To investigate the efficacy of immunoadsorption(IA)in combination with tacrolimus(FKS06)and mycophenolate mofetil(MMF)in the treatment of C4d-positive acute humor- al rejection(AHR)of renal transplants.
    目的探讨免疫吸附(IA)联合他克莫司(FK506)和霉酚酸酯(MMF)治疗C4d阳性的急性体液性排斥反应(AHR)的临床效果。
短句来源
    RESULTS:Patients in tacrolimus group achieved higher scores than in cyclosporine group in mental health and social health 3~6mo after renal transplantation,and significant difference was noted(P<0.05),while there was no significant difference in physiological health.
    结果:肾移植术后3~6mo,他克莫司组的心理健康和社会健康得分比环孢素组高,有显著性差异(P<0.05),在生理健康上无显著性差异;
短句来源
    Clinical application of tacrolimus in 30 cases of cadaver renal transplantation
    尸肾移植后应用他克莫司的临床观察
短句来源
    Clinical use of tacrolimus (FK506) in renal transplantation
    肾移植术后应用他克莫司的临床观察
短句来源
更多       
  “tacrolimus”译为未确定词的双语例句
    Effect and clinical significance of Tacrolimus on serum interleukin-2(IL-2),soluble interleukin-2 receptor(sIL-2R) expression in refractory nephrotic syndrome
    普乐可复对难治性肾病综合征患者血清IL-2、sIL-2R的影响及其临床意义
短句来源
    Clinical study of double doses Simulect with Tacrolimus in prevention of acute rejection of kidney transplantation
    双剂舒莱联合普乐可复预防肾移植急性排斥反应的临床研究
短句来源
    The Analysis of Low Tacrolimus Concentrations and Increased Risk of Early Acute Rejection in Renal Transplantation
    肾移植患者低FK-506血药浓度与早期急性排斥的关系研究
短句来源
    Experimental Study of Tacrolimus in Preventing Renal Interstitial Fibrosis in Rats
    普乐可复抑制大鼠肾间质纤维化的研究
短句来源
    Effects of Tacrolimus on the Expression of α-SMA and Bcl-2 in the Kidney of Nephrotoxic Serum Nephritis in Sprague-Dawley Rats
    他可莫司对肾毒血清肾炎大鼠肾脏α-SMA和Bcl-2表达的影响
短句来源
更多       
查询“tacrolimus”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  tacrolimus
Derzeit sind verschiedene Wirkstoffe in klinischer Erprobung: Paclitaxel, Rapamycin, Actinomycin D oder Tacrolimus.
      
Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model
      
Als Alternativen zu Cyclosporin A und Azathioprin wurden Tacrolimus und Mycophenols?ure entwickelt.
      
Die Calcineurininhibitoren Cyclosporin A und Tacrolimus (FK 506) inaktivieren Calcineurin, ein Schlüsselenzym in der Signaltransduktion des T-Zell-Rezeptors.
      
Safety Profile of Concomitant Use of Caspofungin and Cyclosporine or Tacrolimus in Liver Transplant Patients
      
更多          


Objectives To summarize the experiences of clinical use of tacrolimus as an alternative to cyclosporin in cadaver renal transplantation. Methods Blood concentrations and side effects of tacrolimus were observed for 3 months in 30 cases of cadaver renal transplantation. Results Renal functions were returned to normal in the 30 cases after operation. No rejection occurred during the application of tacrolimus. The blood concentrations of tacrolimus were 5~7?μg/L in 3 cases, 8~15?μg/L...

Objectives To summarize the experiences of clinical use of tacrolimus as an alternative to cyclosporin in cadaver renal transplantation. Methods Blood concentrations and side effects of tacrolimus were observed for 3 months in 30 cases of cadaver renal transplantation. Results Renal functions were returned to normal in the 30 cases after operation. No rejection occurred during the application of tacrolimus. The blood concentrations of tacrolimus were 5~7?μg/L in 3 cases, 8~15?μg/L in 25 cases and 32~38?μg/L in 2 cases, respectively. The main side effects of tacrolimus including marrow depression and hyperglycemia. Conclusions Tacrolimus is a highly effective immunosuppressive agent. When blood trough concentrations of tacrolimus are relatively low in the patients with normal renal function, there is no need to increase the dosage of tacrolimus. Tacrolimus is less harmful to liver and may be the best choice as an immunosuppressive therapy for patients with chronic hepatitis or abnormal liver function.

目的 探讨肾移植后应用他克莫司 (FK5 0 6 )的方法、剂量、疗效及副作用。方法  30例尸肾移植患者术后应用他克莫司 ,临床观察 3个月 ,监测血中他克莫司的浓度和副作用。结果  30例患者术后肾功能均恢复正常 ,在应用他克莫司的观察期内无排斥反应发生 ;血中他克莫司的浓度 ,3例为 5~ 7μg/L ,2 5例为 8~ 15 μg/L ,2例为 32~ 38μg/L ;他克莫司的副作用主要为骨髓抑制和血糖升高。结论 他克莫司是一种强效免疫抑制剂 ;用药要个体化 ,不应片面强调他克莫司的血药浓度 ;他克莫司适合慢性肝炎或肝功能损害者使用 ;突出副作用为骨髓抑制和血糖升高

Objectives To compare the effect and safety of tacrolimus (FK506) with cyclosporin (CsA) in renal transplantation. Methods A total of 35 first cadaveric kidney transplant recipients were randomized to receive FK506 based ( n =20) or CsA based ( n =15) triple therapy after transplantation. The immunosuppressive effects and side reactions were observed in both two groups. Results The 1 year person/graft survival rate in FK506 and CsA groups was 100.0% and 93.3%, 95.0% and 95.0% , respectively...

Objectives To compare the effect and safety of tacrolimus (FK506) with cyclosporin (CsA) in renal transplantation. Methods A total of 35 first cadaveric kidney transplant recipients were randomized to receive FK506 based ( n =20) or CsA based ( n =15) triple therapy after transplantation. The immunosuppressive effects and side reactions were observed in both two groups. Results The 1 year person/graft survival rate in FK506 and CsA groups was 100.0% and 93.3%, 95.0% and 95.0% , respectively .The differences in liver and renal function, blood glucose and blood potassium between the two groups were not significant ( P > 0.05 ). In FK506 group blood lipid and systolic pressure were obviously lower and the incidence of alkaline phosphatase higher than in CsA group ( P < 0.05 ). Conclusions Tacrolimus is a safe and effective immunosuppressive agent. Combined use of FK506 with MMF may decrease the episodes of acute rejection.

目的 观察他克莫司 (FK5 0 6 )作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的 35例患者随机分为 2组 ,一组给予他克莫司、硫唑嘌呤 (或霉酚酸酯 )和泼尼松(FK5 0 6组 ) ,另一组给予环孢素A、硫唑嘌呤 (或霉酚酸酯 )及泼尼松 (CsA组 ) ,观察 2个组的免疫抑制效果及药物的副作用。结果 CsA组和FK5 0 6组的人 /肾 1年存活率分别为 10 0 .0 % / 93 .3 %和95 .0 % / 95 .0 % ;两组肝和肾的功能、血糖、血钾的差异无显著性 ;FK5 0 6组的血脂及收缩压明显低于CsA组 ;FK5 0 6组的碱性磷酸酶升高的发生率较CsA组高 ,差异有显著性 (P <0 .0 5 )。结论 他克莫司是肾移植术后强有力的免疫抑制剂 ;与霉酚酸酯联合用药可减少急性排斥反应的发生率目的 观察他克莫司 (FK5 0 6 )作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的 35例患者随机分为 2组 ,一组给予他克莫司、硫唑嘌呤 (或霉酚酸酯 )和泼尼松(FK5 0 6组 ) ,另一组给予环孢素A、硫唑嘌呤 (或霉酚酸酯 )及泼尼松 (C...

目的 观察他克莫司 (FK5 0 6 )作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的 35例患者随机分为 2组 ,一组给予他克莫司、硫唑嘌呤 (或霉酚酸酯 )和泼尼松(FK5 0 6组 ) ,另一组给予环孢素A、硫唑嘌呤 (或霉酚酸酯 )及泼尼松 (CsA组 ) ,观察 2个组的免疫抑制效果及药物的副作用。结果 CsA组和FK5 0 6组的人 /肾 1年存活率分别为 10 0 .0 % / 93 .3 %和95 .0 % / 95 .0 % ;两组肝和肾的功能、血糖、血钾的差异无显著性 ;FK5 0 6组的血脂及收缩压明显低于CsA组 ;FK5 0 6组的碱性磷酸酶升高的发生率较CsA组高 ,差异有显著性 (P <0 .0 5 )。结论 他克莫司是肾移植术后强有力的免疫抑制剂 ;与霉酚酸酯联合用药可减少急性排斥反应的发生率目的 观察他克莫司 (FK5 0 6 )作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的 35例患者随机分为 2组 ,一组给予他克莫司、硫唑嘌呤 (或霉酚酸酯 )和泼尼松(FK5 0 6组 ) ,另一组给予环孢素A、硫唑嘌呤 (或霉酚酸酯 )及泼尼松 (CsA组 ) ,观察 2个组的免疫抑制效果及药物的副作用。结果 CsA组和FK5 0 6组的人 /肾 1年存活率分别为 10 0 .0 % / 93 .3 %和95 .0 % / 95 .0 % ;两组肝和肾的功能、血糖、血钾的差异无显著性 ;FK5 0

Objective To evaluate the efficacy and safety of CsA substituted by tacrolimus (FK506) combined with MMF and prednisone in prevention of rejection in renal transplant recipents with hepatic dysfunction. Methods Eight patients with hepatic dysfunction received the treatment of FK506 substituting for CsA. FK506 was administeted at least 24?h after the last dose of cyclosporine. The initial dose of FK506 was based on body weight, the degree of hepatic dysfunction and the period after operation of the patients....

Objective To evaluate the efficacy and safety of CsA substituted by tacrolimus (FK506) combined with MMF and prednisone in prevention of rejection in renal transplant recipents with hepatic dysfunction. Methods Eight patients with hepatic dysfunction received the treatment of FK506 substituting for CsA. FK506 was administeted at least 24?h after the last dose of cyclosporine. The initial dose of FK506 was based on body weight, the degree of hepatic dysfunction and the period after operation of the patients. After administration of one week, the dose of FK506 was subsequently adjusted to maintain its whole blood trough levels between 5~15?μg/L. Results Substitute of tacrolimus for cyclosporin resulted in a markedly reduced blood index, direct bilirubin from( 22.66 ± 17.19 )μmol/L to ( 7.05 ± 2.32 )μmol/L ( P < 0.05 ), indirect bilirubin from ( 42.15 ± 34.15 )μmol/L to ( 14.54 ± 2.59 )μmol/L ( P < 0.05 ), sALT from ( 83.00 ± 93.14 )IU/L to ( 29.50 ± 15.41 ) IU/L ( P > 0.05) , Cr from ( 177.91 ± 86.41 )μmol/L to ( 135.92 ± 34.05 )μmol/L ( P > 0.05 ) in one month. The ascites of 3 patients disappeared in one month. Astriction, anorexia, upper limbs trembling appeared only in one patient. Conclusion It is effective and safe to substitute CsA by FK506 combined with MMF and prednisone in prevention of rejection in renal transplant recipients with hepatic dysfunction.

目的 观察他克莫司 (FK5 0 6 )替换环孢素A(CsA)并联合应用霉酚酸酯 (MMF)及泼尼松 (Pred)防治肾移植术后肝功能异常患者的有效性及安全性。方法 肾移植术后 8例肝功能异常患者 (男性 5例 ,女性 3例 ,平均 38.2 3岁 ) ,用FK5 0 6替换CsA治疗 ,停用CsA 2 4h后 ,开始给予FK5 0 6。FK5 0 6初始剂量根据患者体重、肝功能损害程度及术后时间确定 ,服药 1周后 ,根据全血FK5 0 6谷值浓度调整剂量 ,使其谷值浓度维持于 5~ 15 μg/L。结果 用FK5 0 6替换CsA ,1个月后患者血中直接胆红素从替换前的 (2 2 .6 6± 17.19) μmol/L下降至 (7.0 5± 2 .32 ) μmol/L ,P <0 .0 5 ;间接胆红素从替换前的 (4 2 .15± 34.15 ) μmol/L下降至 (14.5 4± 2 .5 9) μmol/L ,P <0 .0 5 ;血清丙氨酸转氨酶从替换前的 (83 .0 0± 93 .14)IU/L下降至 1个月后的 (2 9.5 0± 15 .41)IU/L ,P >0 .0 5 ;血清肌酐...

目的 观察他克莫司 (FK5 0 6 )替换环孢素A(CsA)并联合应用霉酚酸酯 (MMF)及泼尼松 (Pred)防治肾移植术后肝功能异常患者的有效性及安全性。方法 肾移植术后 8例肝功能异常患者 (男性 5例 ,女性 3例 ,平均 38.2 3岁 ) ,用FK5 0 6替换CsA治疗 ,停用CsA 2 4h后 ,开始给予FK5 0 6。FK5 0 6初始剂量根据患者体重、肝功能损害程度及术后时间确定 ,服药 1周后 ,根据全血FK5 0 6谷值浓度调整剂量 ,使其谷值浓度维持于 5~ 15 μg/L。结果 用FK5 0 6替换CsA ,1个月后患者血中直接胆红素从替换前的 (2 2 .6 6± 17.19) μmol/L下降至 (7.0 5± 2 .32 ) μmol/L ,P <0 .0 5 ;间接胆红素从替换前的 (4 2 .15± 34.15 ) μmol/L下降至 (14.5 4± 2 .5 9) μmol/L ,P <0 .0 5 ;血清丙氨酸转氨酶从替换前的 (83 .0 0± 93 .14)IU/L下降至 1个月后的 (2 9.5 0± 15 .41)IU/L ,P >0 .0 5 ;血清肌酐从 (177.91±86 .41) μmol/L下降至 (135 .92± 34.0 5 ) μmol/L ,P >0 .0 5。 3例腹水的患者均于药物替换 1个月后完全消失。仅有 1例患者出现便秘、食欲下降伴上肢颤抖。结论 用FK5 0 6替换CsA并联合应用MMF及Pred对防治肾移植术后肝功能异常是安全和有效的措施

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关tacrolimus的内容
在知识搜索中查有关tacrolimus的内容
在数字搜索中查有关tacrolimus的内容
在概念知识元中查有关tacrolimus的内容
在学术趋势中查有关tacrolimus的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社